Japan Tissue Engineering Co., Ltd.

Tokyo Stock Exchange 7774.T

Japan Tissue Engineering Co., Ltd. Total Non-Current Liabilities for the year ending March 31, 2024: USD 230.58 K

Japan Tissue Engineering Co., Ltd. Total Non-Current Liabilities is USD 230.58 K for the year ending March 31, 2024, a -12.22% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Japan Tissue Engineering Co., Ltd. Total Non-Current Liabilities for the year ending March 31, 2023 was USD 262.69 K, a -8.73% change year over year.
  • Japan Tissue Engineering Co., Ltd. Total Non-Current Liabilities for the year ending March 31, 2022 was USD 287.80 K, a -10.91% change year over year.
  • Japan Tissue Engineering Co., Ltd. Total Non-Current Liabilities for the year ending March 31, 2021 was USD 323.05 K, a -5.02% change year over year.
  • Japan Tissue Engineering Co., Ltd. Total Non-Current Liabilities for the year ending March 31, 2020 was USD 340.14 K, a -0.62% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
SV Wall Street
Tokyo Stock Exchange: 7774.T

Japan Tissue Engineering Co., Ltd.

CEO Mr. Ken-Ichiro Hata D.D.S., Ph.D.
IPO Date Dec. 28, 2007
Location Japan
Headquarters 6-209-1 Miyakitadori
Employees 211
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.

StockViz Staff

January 31, 2025

Any question? Send us an email